These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 29417238)

  • 1. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
    Friedman CF; Hensley ML
    Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
    Roque DR; Taylor KN; Palisoul M; Wysham WZ; Milam B; Robison K; Gehrig PA; Raker C; Kim KH
    Int J Gynecol Cancer; 2016 Mar; 26(3):505-11. PubMed ID: 26807641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of adjuvant therapy in uterine leiomyosarcoma.
    Ducie JA; Leitao MM
    Expert Rev Anticancer Ther; 2016; 16(1):45-55. PubMed ID: 26558647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of adjuvant treatment for morcellated, International Federation of Gynecology and Obstetrics stage I uterine leiomyosarcoma: A Korean multicenter study.
    Kim SI; Choi CH; Kim K; Hong DH; Park JY; Kwon BS; Lee KH; Hong DG; Shin SJ; Park SI; Kim YH; Lee SH; Lee S; Hong JH; Lee JY; Kim YB; No JH; Suh DH
    J Obstet Gynaecol Res; 2020 Feb; 46(2):337-346. PubMed ID: 31814199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
    Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
    Littell RD; Tucker LY; Raine-Bennett T; Palen TE; Zaritsky E; Neugebauer R; Embry-Schubert J; Lentz SE
    Gynecol Oncol; 2017 Oct; 147(1):11-17. PubMed ID: 28747255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
    Diggs A; Sia TY; Huang Y; Gockley A; Melamed A; Khoury-Collado F; St Clair C; Hou JY; Hershman DL; Wright JD
    Gynecol Oncol; 2022 Aug; 166(2):308-316. PubMed ID: 35660331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
    Hensley ML; Wathen JK; Maki RG; Araujo DM; Sutton G; Priebat DA; George S; Soslow RA; Baker LH
    Cancer; 2013 Apr; 119(8):1555-61. PubMed ID: 23335221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
    Ricci S; Giuntoli RL; Eisenhauer E; Lopez MA; Krill L; Tanner EJ; Gehrig PA; Havrilesky LJ; Secord AA; Levinson K; Frasure H; Celano P; Fader AN
    Gynecol Oncol; 2013 Dec; 131(3):629-33. PubMed ID: 24016408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study.
    Guttmann DM; Li H; Sevak P; Grover S; Jacobson G; Feldman A; Rubin S; Chu C; Bhatia S; Elshaikh MA; Lin LL
    Int J Gynecol Cancer; 2016 Jan; 26(1):141-8. PubMed ID: 26509850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of adjuvant treatment on oncologic outcomes in patients with stage I leiomyosarcoma of the uterus.
    Boyraz G; Başaran D; Salman MC; Özgül N; Yüce K
    Turk J Med Sci; 2017 Jun; 47(3):841-846. PubMed ID: 28618731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
    Chae SH; Shim SH; Chang M; Choi AY; Kang GG; Lee SJ; Kim SN
    Gynecol Oncol; 2019 Sep; 154(3):638-650. PubMed ID: 31307664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
    Akin S; Dizdar O; Karakas Y; Turker A; Kars A
    Curr Probl Cancer; 2018; 42(3):344-349. PubMed ID: 29576383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant treatment for uterine leiomyosarcoma.
    Akers SN; Groman A; Odunsi K; Lele S; Frederick PJ
    Eur J Gynaecol Oncol; 2013; 34(5):409-14. PubMed ID: 24475573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in the treatment of uterine leiomyosarcoma in the Medicare population.
    Foley OW; Rauh-Hain JA; Clemmer J; Clark RM; Hall T; Diver EJ; Schorge JO; del Carmen MG
    Int J Gynecol Cancer; 2015 Mar; 25(3):453-8. PubMed ID: 25628107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uterine Leiomyosarcoma.
    Juhasz-Böss I; Gabriel L; Bohle RM; Horn LC; Solomayer EF; Breitbach GP
    Oncol Res Treat; 2018; 41(11):680-686. PubMed ID: 30321869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.
    Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1277-87. PubMed ID: 18506484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive Surgery and HIPEC as a Treatment Option for Laparoscopic Resection of Uterine Leiomyosarcoma with Morcellation: Early Results.
    Sugarbaker P; Ihemelandu C; Bijelic L
    Ann Surg Oncol; 2016 May; 23(5):1501-7. PubMed ID: 26545375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.